Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Pharma
BMS, Merck, Amgen and more face near-term generic woes: Leerink
As patent expirations near for many of the world’s top drugmakers, companies will need to be diligent about M&A, according to a new Leerink report.
Fraiser Kansteiner
Nov 13, 2024 10:57am
AZ, Merck's Koselugo delivers trial win in adults with NF1
Nov 13, 2024 9:06am
AZ tacks on $2B to its investment in US manufacturing, R&D
Nov 12, 2024 10:10am
AstraZeneca CEO defends $80B revenue target amid China probes
Nov 12, 2024 9:40am
Amgen, AZ's Tezspire excels in phase 3 rhinosinusitis trial
Nov 8, 2024 3:31pm
AZ China fallout, Pfizer's $1B plan in China—Fierce Pharma Asia
Nov 8, 2024 8:54am
